Screener
Regeneron Pharmaceuticals REGN Outside United States — Property, plant, and equipment, net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization.
The source filing: Regeneron Pharmaceuticals’s 10-K, filed February 4, 2026.
- Filed
- Feb 4, 2026, 9:08 AM EST
- Fiscal year
- FY2025
- Accession
- 0000872589-26-000008
As of December 31, 2025 and 2024, $4.332 billion and $3.884 billion, respectively, of the Company's net property, plant, and equipment was located in the United States and $788.0 million and $715.9 million, respectively, was located outside the United States (primarily in Ireland).
Item 16. Form 10-K Summary
FAQ
- What is Regeneron Pharmaceuticals's outside united states — property, plant, and equipment, net?
- Regeneron Pharmaceuticals (REGN) reported outside united states — property, plant, and equipment, net of $788M in Q4 2025.
- What does outside united states — property, plant, and equipment, net mean?
- This metric represents the net book value of tangible long-term assets, such as manufacturing facilities, laboratories, and distribution centers, located outside of the company's home country. It reflects the capital investment required to support international operations, including global supply chain infrastructure and regional research capabilities. Monitoring this figure helps investors assess the geographic footprint and the scale of physical assets dedicated to non-domestic markets.
Ask your AI about Regeneron Pharmaceuticals's outside united states — property, plant, and equipment, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude